LDOS vs NBIX · P/E 16, rev $8.96B vs P/E 45, rev $1.77B
Leidos Holdings Inc (LDOS) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Leidos Holdings Inc (LDOS) is a information technology services company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported LDOS revenue for 2026-07-03 was $8.96B. Net income was $682.0M. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
LDOS currently screens at market cap $20.04B and trailing P/E 15.7. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the LDOS and NBIX stock pages for the full models.
Not investment advice.